The FDA has selected influenza vaccine strains for the 2025 to 2026 U.S. flu season, maintaining consistency with prior formulations while incorporating updated epidemiologic and antigenic data to optimize protection.
Despite declines in tobacco use, adults with disabilities had higher usage rates. Differences in use across cumulative disabilities persisted or worsened, the study found.
The FDA's 2025 pulse oximetry guidance introduces stricter accuracy standards, larger study cohorts, and objective skin pigmentation assessment to address measurement bias in darker-skinned patients.
New interchangeable treatment option Omlyclo now available for patients with allergic asthma, chronic hives, nasal polyps, and food allergies; carries same boxed warning for anaphylaxis as original medication.
The WAYPOINT trial provides strong evidence that tezepelumab effectively reduces nasal polyp size, congestion, and overall symptom burden in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps